Version 1
: Received: 3 May 2024 / Approved: 7 May 2024 / Online: 7 May 2024 (11:52:18 CEST)
How to cite:
Thavarajah, J. J.; Hønge, B. L.; Wejse, C. M. The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention. Preprints2024, 2024050383. https://doi.org/10.20944/preprints202405.0383.v1
Thavarajah, J. J.; Hønge, B. L.; Wejse, C. M. The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention. Preprints 2024, 2024050383. https://doi.org/10.20944/preprints202405.0383.v1
Thavarajah, J. J.; Hønge, B. L.; Wejse, C. M. The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention. Preprints2024, 2024050383. https://doi.org/10.20944/preprints202405.0383.v1
APA Style
Thavarajah, J. J., Hønge, B. L., & Wejse, C. M. (2024). The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention. Preprints. https://doi.org/10.20944/preprints202405.0383.v1
Chicago/Turabian Style
Thavarajah, J. J., Bo Langhoff Hønge and Christian Morberg Wejse. 2024 "The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention" Preprints. https://doi.org/10.20944/preprints202405.0383.v1
Abstract
Background: Although antiretroviral therapy (ART) effectively halt disease progression in HIV infections, complete eradiation of the virus remains elusive. Additionally, challenges such as long-term ART toxicity, drug resistance, and the demanding regimen of daily and lifelong ad-herence required by ART highlight the imperative need for alternative therapeutic and preventa-tive approaches. In recent years, broadly neutralizing antibodies (bNAbs) have emerged as promising candidates, offering potential for therapeutic, preventative and possibly curative in-terventions against HIV infection.
Objective: This review aims to provide a comprehensive overview of the current state of knowledge regarding the passive immunization of bNAbs in HIV-1 infected individuals.
Main findings: Recent findings from clinical trials have highlighted the potential of bNAbs in treatment, prevention, and in the quest of an HIV-1 cure. While monotherapy with a single bNAb is insufficient in maintaining viral suppression and preventing viral escape, ultimately leading to viral rebound, combination therapy with potent, non-overlapping epitope-targeting bNAbs have demonstrated prolonged viral suppression and delayed time to rebound by effec-tively restricting the emergence of escape mutations, albeit largely in individuals with bNAb-sensitive strains. Additionally, passive immunization of bNAb have provided ‘proof-of-concept’ for antibody-mediated prevention against HIV-1 acquisition, although com-plete prevention was not obtained. Therefore, further research on the use of bNAbs in HIV-1 treatment and prevention remains imperative.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
